RESEARCH NOTE

- 2 Real-life evaluation of a rapid antigen test (PanbioTM COVID-19 Ag Rapid Test
- 3 Device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19
- 4 patients

1

- 5 Ignacio Torres¹, Sandrine Poujois¹, Eliseo Albert¹, Javier Colomina¹, and David
- 6 Navarro^{1,2*}
- 7 ¹Microbiology Service, Hospital Clínico Universitario, INCLIVA Research Institute,
- 8 Valencia, Spain.
- ²Department of Microbiology, School of Medicine, University of Valencia, Valencia,
- 10 Spain.

11

17

18

19

20

21

- 12 *Correspondence: David Navarro, Microbiology Service, Hospital Clínico
- 13 Universitario, Instituto de Investigación INCLIVA, Valencia, and Department of
- 14 Microbiology, University of Valencia, Valencia, Spain. Av. Blasco Ibáñez 17, 46010
- 15 Valencia, Spain. Phone: 34(96)1973500; Fax: 34(96)3864173; E-mail:
- 16 david.navarro@uv.es.

ABSTRACT

23

- 24 **Objectives**: There is limited information on the performance of rapid antigen detection
- 25 (RAD) tests to identify SARS-CoV-2-infected asymptomatic individuals. In this field
- 26 study, we evaluated the PanbioTM COVID-19 Ag Rapid Test Device (Abbott
- 27 Diagnostics, Jena, Germany) for the purpose.
- 28 **Methods:** A total of 634 individuals (355 female; median age, 37 years; range, 9-87)
- 29 were enrolled. Household (n=338) contacts were tested at a median of 2 days (range, 1-
- 30 7) after diagnosis of the index case and non-household contacts (n=296) at a median of
- 31 6 days (range, 1-7) after exposure. RAD testing was carried out at the point of care. The
- 32 RT-PCR test used was the TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific,
- 33 Massachusetts, USA).
- 34 **Results**: In total, 79 individuals (12.4%) tested positive by RT-PCR, of whom 38
- 35 (48.1%) yielded positive RAD results. The overall sensitivity and specificity of the
- 36 RAD test was 48.1% (95% CI: 37.4-58.9) and 100% (95% CI: 99.3-100), respectively.
- 37 Sensitivity was higher in household (50.8%; 95% CI: 38.9-62.5) than in non-household
- 38 (35.7%; 95% CI:16.3-61.2%) contacts. Individuals testing positive by RAD test were
- more likely (P<0.001) to become symptomatic than their negative counterparts.
- 40 **Conclusion**: The Panbio test displays low sensitivity in asymptomatic close contacts of
- 41 COVID-19 patients, particularly in non-household contacts. Nonetheless, establishing
- 42 the optimal timing for upper respiratory tract collection in this group seems imperative
- 43 to pinpoint test sensitivity.

- 45 **KEYWORDS:** SARS-CoV-2, COVID-19, rapid antigen detection test (RAD),
- 46 asymptomatic, close contacts.

INTRODUCTION

47

Rapid antigen detection (RAD) immunoassays have emerged as a valuable alternative to 48 RT-PCR for diagnosis of SARS-CoV-2 infection in patients presenting with clinically 49 compatible COVID-19 [1]. RAD tests are simple to carry out and return results within a 50 51 short time, thus being well-suited for point-of-care testing (POCT). Moreover, RAD tests can be used as a proxy for SARS-CoV-2 cultured from respiratory tract specimens, 52 53 thus allowing reasonably accurate prediction of contagiousness [2,3]. The possibility of 54 using RAD tests to identify SARS-CoV-2-infected asymptomatic contacts of COVID-55 19 patients is appealing, as it could effectively contribute to minimize community 56 SARS-CoV-2 spread through early detection of highly infectious individuals [1], yet 57 little is known about how RAD tests perform in this population group [4-6]. Here, we 58 report on the performance of the PanbioTM COVID-19 Ag Rapid Test Device (Abbott Diagnostic GmbH, Jena, Germany) conducted at POC in this setting. 59

60 Material and methods

Patients

61

66

67

68

69

70

62 A total of 634 consecutive asymptomatic individuals (female, n=355; median age, 37

63 years; range, 9-87 years) attended at the Clínico-Malvarrosa Health Department

64 (Valencia, Spain) were enrolled between October 16 and November 20, 2020.

Participants were either household (n=338) or non-household (n=296) close contacts of

COVID-19 patients, as defined by the Spanish Ministry of Health [7]. Timing of sample

collection was prescribed at the discretion of either the physician in charge of the index

case or local health authorities. The study was approved by the Hospital Clínico de

Valencia (HCU) INCLIVA Research Ethics Committee.

SARS-CoV-2 testing

71 Nasopharyngeal swabs (NP) for RAD and RT-PCR testing were collected by

experienced nurses at the POC site located at Hospital Malvarrosa, as previously

73 detailed [3]. RAD testing was carried out at POC immediately after sampling. RT-PCRs

74 were conducted within 24 h. of specimen collection at the Microbiology Service of

75 Hospital Clínico Universitario (Valencia, Spain) with the TaqPath COVID-19 Combo

76 Kit (Thermo Fisher Scientific, Massachusetts, USA). RT-PCR Ct values were

77 normalized to copies/ml as previously described [3].

Statistical analyses

- 79 Agreement between RAD and RT-PCR tests was assessed using Cohen's Kappa (κ)
- 80 statistics. Differences between medians were compared using the Mann-Whitney U-test.
- 81 The Chi-squared test was used for frequency comparisons. Two-sided *P*-values <0.05
- 82 were considered statistically significant. Statistical analyses were performed using SPSS
- version 25.0 (SPSS, Chicago, IL, USA).

84 **Results**

72

78

85 Overall performance of the RAD test in asymptomatic close contacts

- A total of 79 out of 634 individuals (12.4%) tested positive by RT-PCR, of whom 38
- 87 (48.1%) returned positive RAD test results. There were no RT-PCR positive/RAD
- 88 negative cases. Accordingly, concordance between RT-PCR and RAD results was
- 89 moderate (κ index, 0.61; 95% CI, 0.5-0.73). As shown in Figure 1, SARS-CoV-2 RNA
- 90 load in NP was significantly higher (P<0.001) in RAD-positive (median, 8.7 log₁₀
- 91 copies/ml) than in RAD-negative individuals (4.9 log₁₀ copies/ml).
- 92 Overall sensitivity and specificity of RAD was 48.1% and 100% (Table 1). For the
- 93 above-mentioned prevalence (12.4%), the negative predictive value (NPV) of the RAD
- 94 test was 94.5%. As expected, RAD sensitivity was directly related to SARS-CoV-2 load

- 95 in NP specimens (Supplementary Table 1), reaching 96.8% when specimens with viral
- load \geq 7.4 log10 copies/ml (Ct \leq 20) were analyzed separately.
- 97 Performance of RAD test in household and non-household asymptomatic close
- 98 contacts
- 99 Household contacts (n=338; median age, 36.5; range, 10-86 years; 175 female) were
- tested at a median of 2 days (range, 1-7) after diagnosis of the presumed index case.
- 101 Sixty-five (19.2%) tested positive by RT-PCR, of whom 33 (50.7%) were positive by
- 102 RAD test. The likelihood of obtaining either a positive or a negative RAD result was
- unrelated to the time elapsed since diagnosis of the index case (P=0.33).
- Non-household contacts (n=296; median age, 38.5 years; range, 9-87 years; 180 female)
- 105 were tested at a median of 6 days (range, 1-7) after self-reported exposure. Five
- individuals yielded RT-PCR-positive/RAD-positive results (1.6%) and 9 had RT-PCR-
- positive/RAD-negative results (3.0%). Overall, median time from exposure to testing
- 108 was similar among individuals displaying either positive or negative RAD results
- 109 (*P*=0.89).
- 110 The agreement level between RT-PCR and RAD results was significantly higher
- 111 (P<0.001) for household (κ , 0.61; 95% CI, 0.50-0.75) than for non-household (κ , 0.51;
- 112 95% CI, 0.20-0.83) contacts. RAD sensitivity was significantly higher (P < 0.001) in
- 113 household contacts, while the opposite was true for NPV (Table 1).
- 114 SARS-CoV-2 RNA load was comparable (P=0.21) across household (median, 6.8 \log_{10}
- copies/ml; range, 3.4-10.9) and non-household (median, 5.9 log₁₀ copies/ml; range, 3.5-
- 116 10.6) contacts, and was significantly higher (P<0.001) in RAD-positive than in RAD-
- 117 negative individuals, irrespective of the subcohort considered.

Clinical outcomes

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

Thirty-nine out of the 79 individuals testing positive by RT-PCR eventually became mildly symptomatic (49.3%), without requiring hospitalization. Individuals testing positive by RAD were more likely (P<0.001) to develop COVID-19 (30 out of 38) than those who did not (9 out of 41). **Discussion** In this field study, overall sensitivity of the PanbioTM COVID-19 Ag Rapid Test Device for identification of SARS-CoV-2-infected individuals among asymptomatic close contacts of confirmed COVID-19 cases was 48.1%, close to the figures reported by Linares et al. (54.5%) [4], Fenollar et al. (45.4%) [5] and Bulilete et al. (59.0%) [6], in apparently comparable cohorts. However, in two of these studies [4,5], the RAD test was carried out at a central laboratory, and timing of sample collection was not disclosed [4,5]. In the study by Bulilete at al. [5] most participants (70.6%) were tested within 5 days of exposure. Sensitivity of the PanbioTM test was lower than was previously found [3-6] in symptomatic patients (around 80%), yet as reported for the latter patients, RAD sensitivity was directly related to the magnitude of SARS-CoV-2 RNA load in NP specimens. Such a striking difference might reflect dissimilarities across symptomatic and asymptomatic individuals in the kinetics of SARS-CoV-2 load in the upper respiratory tract [8,9]. While it is well known that SARS-CoV-2 load peaks around the time of symptoms onset in the former group [10,11], the timing is uncertain in asymptomatic cases. Interestingly, individuals testing positive by RAD were more likely to become (mildly) symptomatic than their negative counterparts, pointing to a pathogenetic link between

SARS-CoV-2 RNA load and development of overt COVID-19.

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

AUTHOR'S CONTRIBUTIONS

The strength of the current study is that it reflects the real-life performance of the RAD test at POC. Among its limitations are the relative low number of cases, and the possibility that samples were collected too early after exposure, particularly in nonhousehold contacts, in whom RAD sensitivity was strikingly low. In this sense, Linares et al. [4] reported the sensitivity of the PanbioTM test as very low in close contacts at less than 7 days from exposure. In summary, we found the PanbioTM test to display low sensitivity in asymptomatic contacts of COVID-19 patients. Nevertheless, establishing the optimal timeframe for NP collection in household and non-household contacts seems crucial to accurately determine the sensitivity of the test. **ACKNOWLEDGMENTS** We are grateful to Abbott Diagnostics for providing the PanbioTM COVID-19 Ag Rapid Test Device kits. We thank all personnel working at Clinic University Hospital and primary healthcare centers belonging to the Clínico Malvarrosa Health Department for their unwavering commitment in the fight against COVID-19. We would also like to thank María José Beltrán, Pilar Botija and Ana Sanmartín for assistance in organizing RAD testing in primary healthcare centers and Salvador Peiró for critical revision of the manuscript. FINANCIAL SUPPORT This work received no public or private funds. **CONFLICTS OF INTEREST** The authors declare no conflicts of interest.

- 165 IT, SP and EA: Methodology and data validation. EA, IT and JC: Formal analysis. DN:
- 166 Conceptualization, supervision, writing the original draft. All authors reviewed the
- 167 original draft.

168

REFERENCES

- 169 1. Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the
- UK. https://www.ecdc.europa.eu/en/publications-data/options-use-rapid-antigen-
- tests-covid-19-eueea-and-uk. November 19.
- 172 2. Pekosz A, Cooper C, Parvu V, Li M, Andrews J, Manabe YC, Kodsi S, et al.
- Antigen-based testing but not real-time PCR correlates with SARS-CoV-2 virus
- 174 culture. medRxiv 2020.10.02.20205708; doi:
- https://doi.org/10.1101/2020.10.02.20205708.
- 176 3. Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernández-Fuentes MÁ, et al.
- 177 Field evaluation of a rapid antigen test (PanbioTM COVID-19 Ag Rapid Test
- Device) for COVID-19 diagnosis in primary healthcare centers. Clin Microbiol
- 179 Infect. 2020 Nov 12:S1198-743X(20)30697-2.
- 180 4. Linares M, Pérez-Tanoira R, Romanyk J, Pérez-García F, Gómez-Herruz P,
- Arroyo T, et al. Panbio antigen rapid test is reliable to diagnose SARS-CoV-2
- infection in the first 7 days after the onset of symptoms. J Clin Virol
- 183 2020;133:104659.
- 5. Fenollar F, Bouam A, Ballouche M, Fuster L, Prudent E, Colson P, et al.
- Evaluation of the Panbio Covid-19 rapid antigen detection test device for the
- screening of patients with Covid-19. J Clin Microbiol 2020;JCM.02589-20.

- 187 6. Bulilete O, Lorente P, Leiva A, Carandell E, Oliver A, Rojo E, et al. Evaluation
- of the PanbioTM rapid antigen test for SARS-CoV-2 in primary health care
- 189 centers and test sites. medRxiv 2020; doi:
- 190 https://doi.org/10.1101/2020.11.13.20231316.
- 191 7. Estrategia de detección precoz, vigilancia y control de COVID-19.
- https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov
- /documentos/COVID19_Estrategia_vigilancia_y_control_e_indicadores.pdf.
- November 11 2020.
- 195 8. Zhang Z, Xiao T, Wang Y, Yuan J, Ye H, Wei L, et al. Early viral clearance and
- antibody kinetics of COVID-19 among asymptomatic carriers. medRxiv
- 197 2020.04.28.20083139.
- 198 9. Chau NVV, Thanh Lam V, Thanh Dung N, Yen LM, Minh NNQ, Hung LM, et
- al. The natural history and transmission potential of asymptomatic SARS-CoV-2
- infection. Clin Infect Dis 2020 Jun 4:ciaa711.
- 201 10. Baggio S, L'Huillier AG, Yerly S, Bellon M, Wagner N, Rohr M, et al. SARS-
- 202 CoV-2 viral load in the upper respiratory tract of children and adults with early
- acute COVID-19. Clin Infect Dis 2020 Aug 6:ciaa1157.
- 204 11. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al.
- 205 Virological assessment of hospitalized patients with COVID-2019. Nature
- 206 2020;581:465-9

208 FIGURE LEGEND

Figure 1. RT-PCR cycle thresholds (Ct) (A) and SARS-CoV-2 RNA load (B) in 210 asymptomatic close contacts of COVID-19 patients testing either positive or negative 211 by Panbio™ COVID-19 Ag Rapid Test Device (RAD). The AMPLIRUN® TOTAL 212 SARS-CoV-2 Control (Vircell S.A:, Granada, Spain) was used as the reference material 213 for SARS-CoV-2 RNA load quantitation (in copies/ml, considering RT-PCR Cts for the N gene [3]). P values for comparisons are shown. 215

209

TABLE 1. Performance of the PanbioTM COVID-19 Ag Rapid Test Device for SARS-CoV-2 detection in asymptomatic household and non-household close contacts

Parameter	Population group		
	All individuals	Household	Non-household
		contacts	contacts
Sensitivity % (95%	48.1 (37.4-58.9)	50.8 (38.9-62.5)	35.7 (16.3-61.2)
CI)			
Specificity% (95%	100 (99.3-100)	100 (98.6-100)	100 (98.7-100)
CI)			
Negative predictive	93.1 (90.8-94.9)	89.5 (85.9-92.5)	96.9 (94.2-98.4)
value			
Positive predictive	100 (90.8-100)	100 (89.6-100)	100 (56.6-100)
value			
^a Adjusted to actual prevalence in the respective population group.			







